Free press releases distribution network?

Agency / Source: STEMCELL Technologies, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



STEMCELL Technologies, Inc. Announces StemSpan™ ACF, The First Plasma Component-free Hematopoietic Expansion Media - STEMCELL Technologies, Inc. announced this week the launch of StemSpan™ ACF - Stemcell.com
STEMCELL Technologies, Inc. Announces StemSpan™ ACF, The First Plasma Component-free Hematopoietic Expansion Media

 

PRZOOM - /newswire/ - Vancouver, British Columbia, Canada, 2012/07/17 - STEMCELL Technologies, Inc. announced this week the launch of StemSpan™ ACF - Stemcell.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

STEMCELL Technologies Inc. announced this week the launch of StemSpan™ ACF, a new animal component- free (ACF) and chemically-defined hematopoietic stem cell expansion medium, which contains no animal and human plasma-derived components. While serum-free media is well established, this is the first complete medium available for the culture and expansion of hematopoietic stem cells that is free of animal and human proteins and only contains recombinant and synthetic components.

StemSpan™ ACF presents a huge leap forward in the field of hematopoietic cell culture as it allows researchers to study hematopoiesis and cell therapy development without concerns of transmission of adventitious agents from plasma derived components, or lack of consistency between different lots of human or bovine proteins in other complete media formulations.

“StemSpan™ ACF supports equivalent total nuclear cell and CD34+ cell expansion as the existing highest performance serum-free medium on the market,” said Dr. Bert Wognum, the senior scientist responsible for hematopoietic stem cell expansion medium development at STEMCELL Technologies. “It also supports monocyte to dendritic cell differentiation and might be used by researchers to develop and optimize their own culture systems to generate large numbers of other mature blood cells.”

“We are delighted to build on our track record for providing high performance hematopoietic serum-free media to scientists, by introducing products like StemSpan™ ACF that take the field to a new and highly awaited level,” said Dr. Allen Eaves, CEO and President of STEMCELL Technologies. “We are excited to give scientists products that take their work to the next phase and remove the difficulties associated with plasma-derived components in other serum-free media.”

By adding StemSpan™ ACF to its portfolio, STEMCELL Technologies (Stemcell.com) continues to support the movement of hematopoietic stem cell expansion research toward cell therapy development and clinical relevance. The high-quality StemSpan products include StemSpan™ SFEM, StemSpan H3000, and StemSpan™ ACF for ex vivo expansion of hematopoietic progenitor cells. For more information about StemSpan™ ACF and for technical resources on hematopoietic stem cell expansion, please visit our product page.

Contact
Isis Carter, PhD, Product Manager
STEMCELL Technologies Inc. P: 604-668-0875

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: STEMCELL Technologies, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


STEMCELL Technologies, Inc. Announces StemSpan™ ACF, The First Plasma Component-free Hematopoietic Expansion Media

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Stemcell |
Contact: Press Office - Stemcell.com 
604-877-0713
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any STEMCELL Technologies, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From STEMCELL Technologies, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  JobsWare.com

Visit  Intrinsic Executive Search Ltd

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today